Impaired linear growth has been shown to occur in individuals treated during childhood with single-dose and fractionated total body irradiation (TBI) before stem cell transplantation. Our objective was to describe the final heights attained and patient/treatment factors correlating with final height in a cohort of childhood cancer survivors treated with hyperfractionated TBI (total dose 1375 or 1500 cGy). Thirty individuals (18 men In conclusion, treatment with hyperfractionated TBI is associated with a reduction in standing height and an even greater reduction in sitting height. Final height after hyperfractionated TBI was similar to that reported after fractionated TBI.
Introduction
Advances in stem cell transplantation (SCT) have resulted in broader indications for this therapeutic modality. 1 Myeloablative regimens used in preparation for SCT include either high-dose chemotherapy or the combination of total body irradiation (TBI) and high-dose chemotherapy. With considerable progress in supportive care, peri-transplant mortality has declined and a growing number of patients treated with SCT during childhood are reaching adulthood. 2 These individuals are at risk of developing long-term complications as a result of their exposure to chemotherapy and radiotherapy and as a consequence of graft-versus-host disease (GVHD). In particular, endocrine disturbances including growth failure, gonadal failure and primary hypothyroidism have been frequently observed in individuals after SCT. 3 Impaired linear growth and reduced final height have been shown to occur in individuals treated during childhood with single-dose and fractionated TBI. [3] [4] [5] [6] [7] Growth hormone (GH) deficiency, resulting from the exposure of the hypothalamus-pituitary region to irradiation may contribute to the height loss, especially in individuals who were treated with cranial radiotherapy before SCT. 6 However, radiation-induced damage to the growth plates, particularly those of the spine, is another possible mechanism for growth failure after TBI. 5, 8 When considering the different schedules of delivering radiotherapy, patients treated with standard fractionated TBI seem to achieve better final heights than those treated with single-dose TBI. 9 The specific effect on final height of hyperfractionated TBI (use of smaller doses administered 2-3 times daily), a treatment modality in use at our center since 1979, has so far not been reported. While theoretically this mode of delivering TBI should result in reduced toxicity to normal tissue, 10 the impact of hyperfractionated TBI on skeletal growth and attained adult-height has not been well studied. 4 We conducted this retrospective study of individuals treated with hyperfractionated TBI at our institution to describe the extent of the height loss incurred and to determine the variables associated with this loss.
Patients and methods

Patients
Inclusion and exclusion criteria. We reviewed the medical records of patients who received SCT at MSKCC between 1 January 1980 and 31 December 2000 and who were assessed in the long-term follow-up clinic (LTFUC) after the completion of all cancer treatments. The LTFUC was established in 1991; nearly 1200 individuals are in active follow-up in this clinic. Patients treated for a malignancy with SCT before the age of 12 years, whose conditioning regimen included TBI, who remained in continuous remission and whose records showed that they had reached their final height by April 2005 were eligible for the study. Individuals were assumed to have reached their final height if they had a bone age X14.5 years in girls or X16 years in boys using the Greulich and Pyle 11 method and/or had a growth velocity p2 cm over a period of 12 months. In all, 30 individuals (18 men) fulfilled the criteria for enrollment in the study.
The study subjects were diagnosed with a malignancy between the ages of 1 and 11.1 years and treated with allogeneic (n ¼ 29) or autologous (n ¼ 1) SCT between the ages of 4.4 and 12 years. The primary diagnoses were: ALL, n ¼ 16; AML, n ¼ 9; non-Hodgkin's lymphoma, n ¼ 3 and CML, n ¼ 2. With the exception of patients treated for CML, all subjects were treated with multi-agent chemotherapy before SCT. In addition, nine of them had been treated with cranial radiotherapy before SCT with doses of 2400 cGy (n ¼ 4) or 1800 cGy (n ¼ 5). None of the patients received cranio-spinal radiation.
Cytoreductive regimens and SCT. All individuals in this study received hyperfractionated TBI as part of their conditioning regimen. 12 TBI was delivered via a linear accelerator in 11 or 12 fractions of 125 cGy each at a dose rate of 8-20 cGy/min. The doses were administered three times daily for 3 days with two or three fractions on day 4 to a total dose of 1375 cGy (n ¼ 10) or 1500 cGy (n ¼ 20). All male patients treated for ALL or AML received an additional 400 cGy dose to the testes (n ¼ 11). A higher dose was used in those with testicular relapse: 600 cGy (n ¼ 1), 900 cGy (n ¼ 1), 1100 cGy (n ¼ 1), 1200 cGy (n ¼ 1) or 1900 cGy (n ¼ 1). Along with TBI, preparation for SCT included high-dose chemotherapy using cyclophosphamide at 60 mg/kg/day for two consecutive days (n ¼ 29) or Ara-C at 3 g/m 2 /dose twice daily for 4 days (n ¼ 1). Cyclophosphamide was combined with another drug in 10 patients: thiotepa (n ¼ 7), VP-16 (n ¼ 2) and etoposide (n ¼ 1).
Complications. All patients were assessed for possible endocrine and non-endocrine sequelae during their followup in the LTFUC. All patients underwent routine testing for major organ system function (that is, cardiac, pulmonary, liver, kidney). The first evaluation was scheduled 1 year after completion of all cancer treatments, and patients were reassessed thereafter at least yearly, or more frequently, depending on their active medical issues. Before the creation of the LTFUC, patients were followed by the BMT Service and referred to specialty clinics as appropriate. (n ¼ 7). A comprehensive evaluation was performed at the time of the first visit of these patients to the LTFUC.
Methods
Standing height and sitting height were measured using a Harpenden stadiometer. These determinations were converted to the number of s.d.'s from the age-and sex-adjusted norms to give s.d. scores (s.d.s.). [13] [14] [15] A child that is average in height will have an s.d.s. of 0. Puberty was assessed using the Tanner stages. 16 Target height was calculated using the following formula: ðMother 0 s height ðcmÞ þ Father 0 s height ðcmÞ þ 13 in boys or À 13 in girlsÞ=2
The bone age estimates, based upon X-rays of the left hand and wrist, were all performed by the same clinician (CS) using the Greulich and Pyle method. 11 The predicted height was calculated using the Bayley-Pinneau method. 17 Thyroid function tests were monitored yearly in all subjects and replacement with levothyroxine was instituted if the thyroid stimulating hormone (TSH) level was elevated above institutional norms. Gonadal function studies (plasma luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels, plasma-estradiol levels in girls and testosterone levels in boys) were performed in all patients starting at age 10 years. In girls with ovarian failure, sex hormone replacement therapy was initiated after the age of 13 years with the starting daily dose of 0.15 mg of conjugated estrogens (Premarin) orally. In boys with Leydig cell dysfunction, testosterone enanthate was used at doses that varied according to the pubertal stage attained at the time therapy was initiated.
Prepubertal, euthyroid patients with a height velocity below À2.0 s.d.s. for age 18 were assessed for GH deficiency using the clonidine and arginine stimulation tests. 19, 20 Peak values of plasma GH levels below 10 ng/ml on both tests were considered indicative of GH deficiency. Replacement therapy with human recombinant GH was offered to GHdeficient patients and initiated at a dose of 0.25 mg/kg/week divided over 6-7 days per week. Patients were not reassessed for GH deficiency after the completion of GH therapy and attainment of final height.
Acute GVHD was treated with glucocorticoids, which were administered for at least 3 months, tapered and discontinued thereafter. Chronic GVHD was diagnosed according to the criteria published by Shulman et al. 21 and treated early on with glucocorticoids. The latter were subsequently tapered slowly over a 6-12 months period.
Statistics
All data reported as mean7s.e. The impact of the different risk factors (patient characteristics and treatment variables) was assessed using the two-sample t-test for binary variables (sex, previous brain radiotherapy, TBI dose p1375 vs 41375 cGy, hypothyroidism, treatment with GH, treatment with sex hormones), analysis of variance for categorical data (previous relapse) and the normal regression model for continuous variables (age at diagnosis, age at TBI, target height). Tables 1 and 2 . The duration of follow-up in the LTFUC ranged between 1.5 and 8.5 years (mean 5.672.0). Seven Final height after hyperfractionated TBI W Chemaitilly et al subjects developed acute GVHD and a total of five subjects suffered from chronic GVHD (currently resolved in all). The endocrine complications detected following BMT included GH deficiency (n ¼ 12), gonadal failure (n ¼ 14) and primary hypothyroidism (n ¼ 11). Other complications included cataracts (n ¼ 8), neuropsychological disorders (n ¼ 7), lung disease (n ¼ 5), cardiomyopathy (n ¼ 3), dyslipidemia (n ¼ 3), thyroid neoplasms (n ¼ 2) and reduced bone mineral density (n ¼ 2). 
Results
Patient characteristics and growth data are summarized in
Height data
Abbreviations: ALL ¼ acute lymphoblastic leukemia; AML ¼ acute myelogenous leukemia; CML ¼ chronic myelogenous leukemia; CRT ¼ cranial radiotherapy; NHL ¼ non-Hodgkin lymphoma; SCT ¼ stem cell transplantation; TBI ¼ total body irradiation. (Figure 2 ). The correlation seemed linear; we were not able to detect a threshold effect for age at TBI vs final height s.d.s. We did not find an association between final height s.d.s. and sex, previous brain irradiation, number of relapses before TBI, dose of TBI, chronic GVHD, treatment with either GH or sex hormone replacement therapy.
Patients with GH deficiency
Nineteen subjects fulfilled the criteria for GH testing (height velocity below À2.0 s.d.s. for age); 12 subjects were found to be GH-deficient, and 7/12 (3 boys and 4 girls) were treated with GH replacement, while the remaining five declined treatment. The mean duration of GH replacement was 3.371.4 years (range 2.3-5.4 years), and it was initiated 4.471.0 years after TBI. Of the seven subjects treated with GH replacement, four had been treated with previous cranial radiotherapy using doses of 1800 cGy (n ¼ 1) or 2400 cGy (n ¼ 3), and one had received an additional 300 cGy to the brain along with TBI. The mean height s.d.s. was À2.070.4 at the beginning of GH replacement (age 12.570.4 years), and remained at À2.070.5 at attainment of final height. The change in height s.d.s. from TBI to final height for individuals treated with GH was less impaired compared to that observed in those not treated with GH (À0.970.2 vs À1.870.2, P ¼ 0.07), but the difference did not achieve statistical significance.
Patients with gonadal failure A total of 14 subjects (seven boys and seven girls) received sex hormone replacement therapy, beginning at a mean age of 17.370.8 in boys and 14.970.6 years in girls. For girls with ovarian failure, sex hormone replacement therapy was invariably needed to induce puberty. In contrast to girls, most boys with Leydig cell dysfunction (six out of seven) were able to initiate pubertal development on their own and required sex hormone replacement therapy for arrested puberty only later. The mean height s. 
Discussion
The mean final height s.d.s. achieved by childhood SCT survivors treated with hyperfractionated TBI at our institution was À1.9, reflecting a mean loss of 1.7 s.d.s.
(equal to approximately 10 cm) from the time of SCT. The target height, a parameter frequently used by clinicians to account for the influence of genetic factors on statural growth, was significantly correlated with the final height. Thus, inherited factors seem to retain an influence on the height outcome, despite the changes caused by cancer and its treatments. Ages at both diagnosis and at treatment with TBI were also significantly correlated with the final height s.d.s. Patients treated with TBI at a young age, and who have many years of linear growth ahead of them, are likely to suffer a greater height-loss than those treated at an older age; younger age at the time of SCT has, indeed, invariably been cited as a major risk factor for short stature in pediatric SCT recipients. 3, 6, 9, [22] [23] [24] [25] [26] [27] [28] [29] The final height data reported by seven other studies are summarized in Table 4 . 9, [22] [23] [24] [25] [26] [27] In contrast to the studies by Bakker et al. 22, 26 and Cohen et al., 9 but in keeping with the findings of others, 23, 25 we did not find a significant interaction between gender and final height. Although the reason for these conflicting findings remain uncertain, differences in the timing and dosing of sex hormone therapy may account for some of the discrepancies in these studies.
Cranial irradiation can affect linear growth by damaging the hypothalamic-pituitary axis and causing GH deficiency. [3] [4] [5] [6] [22] [23] [24] 27, 28 Prior cranial radiotherapy has been cited as a significant risk factor for height loss in many reports of were not able to demonstrate a significant interaction between prior cranial radiotherapy and final height outcome in our cohort of survivors, possibly as a result of the small number of patients who received this treatment (9 out of 30 survivors) and the fact that some patients (4 out of the 9 survivors treated with prior cranial irradiation) received GH-replacement therapy.
The final sitting height s.d.s. in our cohort was severely impaired, with a mean value of À2.2. At the time of the first endocrine assessment, which was on average 3.4 years after TBI, the sitting height had already been affected (mean value of À1.4 s.d.s.), perhaps reflecting an early effect of TBI on spinal growth. Thomas et al. 8 previously reported segmental disproportion in patients treated with single fraction or fractionated TBI 4 years after treatment. These findings favor a direct effect of radiation on the vertebral growth plate as a significant mechanism for the height loss observed following TBI. This may also explain, at least in part, why the height prediction yielded by the bone age performed at the time of the first endocrine assessment consistently overestimated the actual final height (a difference of 1.3 s.d.s.). Irradiation of the long bones may, however, also contribute to the height loss after TBI. 26 The relative contributions of total dose and fractionation schedule of TBI to the final height loss incurred remains a subject of controversy. 6 Frisk et al. 23 and Clement de Boers et al. 24 showed that a significant height loss occurred following single dose TBI in the 750-800 cGy range, a dose below the threshold for growth toxicity suggested by Brauner et al. 5, 30 Patients treated with fractionated TBI achieved a better final height than those treated with single dose TBI, despite receiving a higher total dose in the multicenter study reported by Cohen et al. 9 The dose of TBI administered to our patients using the hyperfractionated mode of administration was in the 1375-1500 cGy range, higher than most other studies with final height data. 9, 23, 24 The narrow range of the doses used in our cohort precluded our ability to detect a dose effect. The final heights attained by patients in our cohort were comparable to those reported following single dose and fractionated TBI at other centers (Table 4) .
The impact of GH replacement on the final heights achieved by pediatric SCT recipients treated with TBI has been difficult to assess. The main target of GH action, the growth plate, may already have suffered significant damage by the time GH treatment was initiated. 30 Nevertheless, Frisk et al. 23 showed that a longer duration of GH therapy improved the height prognosis in SCT recipients who had GH deficiency. Sanders et al. 28 also reported a beneficial effect of GH replacement in pediatric SCT recipients treated with fractionated TBI. Treatment with GH stabilized the height and prevented further loss in height s.d.s. compared with age-matched patients not treated with GH. However, this was only evident for those treated with SCT before the age of 10 years. 28 Similar findings were recently published by Couto-Silva et al. 25 who reported a significant reduction of the height loss by GH replacement for children treated with TBI between the ages of 4 and 8 years. In our cohort, treatment with GH maintained the mean height s.d.s. at À2.0 from the onset of therapy until the attainment of final height.
In conclusion, TBI is associated with reduced final height, which is due in part to the damage it causes to the growth plates of the spine. Final height after hyperfractionated TBI was similar to that observed after fractionated TBI. Genetic factors retain a significant influence on the height outcome despite the diagnosis of cancer and its treatments. Young age at diagnosis and exposure to TBI is associated with a poorer final height outcome. GH therapy appears to prevent further loss in height s.d.s. but does not result in significant catch-up growth.
